Detalhe da pesquisa
1.
Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma.
Cancer Immunol Immunother
; 71(8): 1837-1849, 2022 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-34999916
2.
Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma.
Pediatr Transplant
; 26(3): e14209, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-34907641
3.
Oncolytic Viruses for the Treatment of Metastatic Melanoma.
Curr Treat Options Oncol
; 21(4): 26, 2020 03 19.
Artigo
Inglês
| MEDLINE | ID: mdl-32266483
4.
Correction to: The Role of Oncolytic Viruses in the Treatment of Melanoma.
Curr Oncol Rep
; 20(12): 100, 2018 11 13.
Artigo
Inglês
| MEDLINE | ID: mdl-30426304
5.
The Role of Oncolytic Viruses in the Treatment of Melanoma.
Curr Oncol Rep
; 20(10): 80, 2018 08 25.
Artigo
Inglês
| MEDLINE | ID: mdl-30145781
6.
Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas.
Cancer Immunol Immunother
; 64(9): 1193-203, 2015 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-26076664
7.
Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients.
Melanoma Res
; 34(2): 134-141, 2024 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38181115
8.
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Cancer Res Commun
; 4(4): 1100-1110, 2024 Apr 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38551394
9.
An update on methods for detection of prognostic and predictive biomarkers in melanoma.
Front Cell Dev Biol
; 11: 1290696, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37900283
10.
Combining immunotherapy with high-dose radiation therapy (HDRT) significantly inhibits tumor growth in a syngeneic mouse model of high-risk neuroblastoma.
Heliyon
; 9(6): e17399, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-37408891
11.
Urine Proteomics Link Complement Activation with Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients.
Semin Arthritis Rheum
; 63: 152263, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37802003
12.
InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma.
PLoS One
; 18(4): e0269324, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37011054
13.
Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma.
Oncoimmunology
; 11(1): 2066767, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35558160
14.
Etiologies of Melanoma Development and Prevention Measures: A Review of the Current Evidence.
Cancers (Basel)
; 13(19)2021 Sep 30.
Artigo
Inglês
| MEDLINE | ID: mdl-34638397
15.
Transcriptomic analysis identifies differences in gene expression in actinic keratoses after treatment with imiquimod and between responders and non responders.
Sci Rep
; 11(1): 8775, 2021 04 22.
Artigo
Inglês
| MEDLINE | ID: mdl-33888854
16.
Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma.
Sci Rep
; 11(1): 2809, 2021 02 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33531581
17.
Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec.
Melanoma Res
; 30(4): 410-415, 2020 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32379409
18.
FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab.
Clin Nucl Med
; 45(4): 267-275, 2020 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-32108700
19.
Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma.
Am J Clin Dermatol
; 21(1): 1-11, 2020 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-31602560
20.
Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma.
Cancer Res
; 80(5): 1078-1087, 2020 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31948941